{{Rsnum
|rsid=1596725
|Chromosome=12
|position=65028591
|Orientation=plus
|GMAF=0.3343
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 39.8 | 48.7 | 11.5
| HCB | 32.8 | 50.4 | 16.8
| JPT | 30.1 | 54.0 | 15.9
| YRI | 55.8 | 40.1 | 4.1
| ASW | 50.9 | 38.6 | 10.5
| CHB | 32.8 | 50.4 | 16.8
| CHD | 33.0 | 54.1 | 12.8
| GIH | 47.5 | 44.6 | 7.9
| LWK | 60.0 | 30.9 | 9.1
| MEX | 63.8 | 29.3 | 6.9
| MKK | 44.2 | 42.3 | 13.5
| TSI | 32.4 | 46.1 | 21.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1596725
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19926868
|Annotation=In replicated GWAS in two Asthma family study cohorts, this SNP was found to be associated with the ratio of FEV1(forced expiratory volume in one second) to FVC(forced vital capacity). Risk or phenotype-associated allele: C . Phenotype: higher value for FEV1/FVC. Study size/population/ethnicity: 403 parent -child trios from the Childhood Asthma Management Program (CAMP) and 583 parent-child trios from the Genetics of Asthma in Costa Rica study. Significance metric(s): combined p = 0.003. Type of association: GN
|Drugs=
|Drug Classes=
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA165111748
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1596725
|overall_frequency_n=40
|overall_frequency_d=128
|overall_frequency=0.3125
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}